Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Meningioma risk stratification with a targeted gene-expression biomarker

A validated biomarker risk score based on the expression of 34 genes improves risk stratification of patients with meningioma, including prediction of post-operative radiotherapy benefit.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Discrimination of meningioma outcomes on the basis of the gene-expression biomarker.

References

  1. Chen, W. C. et al. Radiotherapy and radiosurgery for meningiomas. Neurooncol. Adv. 5, i67–i83 (2023). A review that summarizes the literature on meningioma classification and treatment.

    PubMed  PubMed Central  Google Scholar 

  2. Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, 649–659 (2022). A study of meningioma molecular groups using DNA-methylation profiling.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Choudhury, A. et al. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 25, 520–530 (2023). A study of meningioma molecular subgroups using DNA-methylation profiling.

    Article  CAS  PubMed  Google Scholar 

  4. Patel, A. J. et al. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc. Natl Acad. Sci. USA 116, 21715–21726 (2019). A study of meningioma molecular groups using RNA sequencing.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Nassiri, F. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119–125 (2021). A paper reporting a meningioma molecular classification using DNA-methylation profiling, RNA sequencing, copy-number variants and somatic short variants.

    Article  CAS  PubMed  Google Scholar 

  6. Louis, D. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231–1251 (2021). A paper summarizing the 2021 World Health Organization classification of central nervous system tumors.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Chen, W. C. et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat. Med. https://doi.org/10.1038/s41591-023-02586-z (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meningioma risk stratification with a targeted gene-expression biomarker. Nat Med 29, 3020–3021 (2023). https://doi.org/10.1038/s41591-023-02642-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02642-8

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer